Both genetic (2) and pharmacological (3, 4) experiments in such models have demonstrated that reducing the amount of PrP in the brain is protective against prion disease, inspiring hope that a PrP-lowering therapy could be used to effectively treat, delay, and prevent disease in patients and individuals at risk (5). The gene discussed is PRNP; the disease is prion disease.